Risk Factors for Methotrexate Resistance in Low-risk Gestational Trophoblastic Neoplasia Patients (FIGO Score 0-4)

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Apr 9

PMID 38590416

Authors

Tianzhe Jin

Zijun Zhou

Mengmeng Lin

Shuo Yuan

Yite Xue

Taotao Yin

Ruiyi Xu

Bingxin Chen

Jianwei Zhang

Jiehao Sun

Xiao Li

Yan Hu

Lili Chen

Hui Wang

Affiliations

Soon will be listed here.

Abstract

The challenge of methotrexate (MTX) resistance among low-risk gestational trophoblastic neoplasia (GTN) patients has always been prominent. Despite the International Federation of Gynaecology and Obstetrics (FIGO) score of 0-4 patients comprising the majority of low-risk GTN patients, a comprehensive exploration of the prevalence and risk factors associated with MTX resistance has been limited. Therefore, we aimed to identify associated risk factors in GTN patients with a FIGO score of 0-4. Between January 2005 and December 2020, 310 low-risk GTN patients received primary MTX chemotherapy in two hospitals, with 265 having a FIGO score of 0-4. In the FIGO 0-4 subgroup, 94 (35.5%) were resistant to MTX chemotherapy, and 34 (12.8%) needed multi-agent chemotherapy. Clinicopathologic diagnosis of postmolar choriocarcinoma (OR = 17.18, 95% CI: 4.64-63.70, < 0.001) and higher pretreatment human chorionic gonadotropin concentration on a logarithmic scale (log-hCG concentration) (OR = 18.11, 95% CI: 3.72-88.15, < 0.001) were identified as independent risk factors associated with MTX resistance according to multivariable logistic regression. The decision tree model and regression model were developed to predict the risk of MTX resistance in GTN patients with a FIGO score of 0-4. Evaluation of model discrimination, calibration and net benefit revealed the superiority of the decision tree model, which comprised clinicopathologic diagnosis and pretreatment hCG concentration. The patients in the high- and medium-risk groups of the decision tree model had a higher probability of MTX resistance. This study represents the investigation into MTX resistance in GTN patients with a FIGO score of 0-4 and disclosed a remission rate of approximately 65% with MTX chemotherapy. Higher pretreatment hCG concentration and clinicopathologic diagnosis of postmolar choriocarcinoma were independent risk factors associated with resistance to MTX chemotherapy. The decision tree model demonstrated enhanced predictive capabilities regarding the risk of MTX resistance and can serve as a valuable tool to guide the clinical treatment decisions for GTN patients with a FIGO score of 0-4.

References

Eysbouts Y, Massuger L, Thomas C, Ottevanger P, Short D, Harvey R . Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared. Int J Gynecol Cancer. 2016; 26(9):1712-1716. DOI: 10.1097/IGC.0000000000000812. View

Abu-Rustum N, Yashar C, Bean S, Bradley K, Campos S, Chon H . NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020; 18(6):660-666. DOI: 10.6004/jnccn.2020.0027. View

McGrath S, Short D, Harvey R, Schmid P, Savage P, Seckl M . The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer. 2010; 102(5):810-4. PMC: 2833242. DOI: 10.1038/sj.bjc.6605529. View

Parker V, Cushen B, Hills A, Kandiah K, Palmer J, Singh K . Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2022; 169:34-40. DOI: 10.1016/j.ygyno.2022.11.025. View

Hoeijmakers Y, Sweep F, Lok C, Ottevanger P . Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study. BJOG. 2020; 127(9):1139-1145. PMC: 7383780. DOI: 10.1111/1471-0528.16198. View

Venkatraman E . A permutation test to compare receiver operating characteristic curves. Biometrics. 2000; 56(4):1134-8. DOI: 10.1111/j.0006-341x.2000.01134.x. View

Strohl A, Lurain J . Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2016; 141(2):276-280. DOI: 10.1016/j.ygyno.2016.02.014. View

Chen L, Xi L, Jiang J, Yin R, Qu P, Li X . Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial. Front Med. 2021; 16(2):276-284. DOI: 10.1007/s11684-021-0855-4. View

Parker V, Winter M, Tidy J, Palmer J, Sarwar N, Singh K . PREDICT-GTN 2: Two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia. Gynecol Oncol. 2023; 180:152-159. DOI: 10.1016/j.ygyno.2023.11.017. View

10.

Sita-Lumsden A, Short D, Lindsay I, Sebire N, Adjogatse D, Seckl M . Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer. 2012; 107(11):1810-4. PMC: 3504950. DOI: 10.1038/bjc.2012.462. View

11.

Weng Y, Liu Y, Benjoed C, Wu X, Tang S, Li X . Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia: a 19-year retrospective analysis. J Zhejiang Univ Sci B. 2022; 23(3):218-229. PMC: 8913924. DOI: 10.1631/jzus.B2100895. View

12.

Frijstein M, Lok C, van Trommel N, Ten Kate-Booij M, Massuger L, van Werkhoven E . Lung metastases in low-risk gestational trophoblastic neoplasia: a retrospective cohort study. BJOG. 2019; 127(3):389-395. DOI: 10.1111/1471-0528.16036. View

13.

Taylor F, Grew T, Everard J, Ellis L, Winter M, Tidy J . The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. Eur J Cancer. 2013; 49(15):3184-90. DOI: 10.1016/j.ejca.2013.06.004. View

14.

You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage P . Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer. 2013; 108(9):1810-6. PMC: 3664307. DOI: 10.1038/bjc.2013.123. View

15.

Peduzzi P, Concato J, Kemper E, Holford T, Feinstein A . A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49(12):1373-9. DOI: 10.1016/s0895-4356(96)00236-3. View

16.

Chapman-Davis E, Hoekstra A, Rademaker A, Schink J, Lurain J . Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012; 125(3):572-5. DOI: 10.1016/j.ygyno.2012.03.039. View

17.

Eagle S, Grashow R, DiGregorio H, Terry D, Baggish A, Weisskopf M . Interaction of Medical Conditions and Football Exposures Associated with Premortem Chronic Traumatic Encephalopathy Diagnosis in Former Professional American Football Players. Sports Med. 2023; 54(3):743-752. DOI: 10.1007/s40279-023-01942-w. View

18.

Parker V, Winter M, Tidy J, Hancock B, Palmer J, Sarwar N . PREDICT-GTN 1: Can we improve the FIGO scoring system in gestational trophoblastic neoplasia?. Int J Cancer. 2022; 152(5):986-997. PMC: 10108153. DOI: 10.1002/ijc.34352. View

19.

Wu J, Zhang H, Li L, Hu M, Chen L, Xu B . A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. Cancer Commun (Lond). 2020; 40(7):301-312. PMC: 7365459. DOI: 10.1002/cac2.12067. View

20.

Jiang F, Wan X, Xu T, Feng F, Ren T, Yang J . Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients. Gynecol Oncol. 2018; 149(3):539-544. DOI: 10.1016/j.ygyno.2018.04.001. View